Aug 17, 2021/IndustryNewsGlobal/ The unexpected shifts in the global markets because of the sudden outbreak of the COVID-19 virus have brought many major and minor tremors to industries of all sizes including the Cephalosporin Market.
It was estimated prior to this unanticipated outbreak that the Cephalosporin Market was expected to grow at a CAGR of 2.8% during the forecast period. However, the gradual slowing down of industries will undoubtedly impose limits on the previously estimated growth rate.
For a more detailed breakdown of the COVID-19 impact on the Cephalosporin Market, request a free sample of the report here:
The growing prevalence of infectious diseases and the increase in funding for the development of antibiotics are some of the key factors bolstering the product demand. Additionally, the surge in R&D activities for the production of combination drugs and the rising demand for antibacterial further augment the market growth. Moreover, the discovery of innovative prospect molecules and the introduction of novel combination therapies to treat antibiotic-resistant infections are likely to provide lucrative opportunities to the industry participants. However, the side effects of cephalosporin are likely to hinder the industry expansion.
Click here for ToC of the report:
By type, the cephalosporin market has been segmented into branded and generic. Under these, the generic segment held a considerable market share in 2020 and is likely to register the fastest CAGR during the review period. This is mainly attributed to the easy availability of drugs at a lower cost when compared to branded drugs. Also, the pharmacological effects of generic drugs are almost the same as those of their brand-name equivalents.
By region, the Asia Pacific market witnessed the highest market share in 2020 and is estimated to grow at a substantial CAGR during the assessment period. This is mainly ascribed to the rise in consumption of cephalosporin, upsurge in demand for over-the-counter drugs, easier availability, and increasing bacterial infections in the Asia Pacific. Moreover, growing healthcare expenditure and improving standards of living with large population growth further boosts the regional growth.
Key players operating in the global cephalosporin market are-
- Aristo Pharmaceuticals Ltd (India),
- Baxter International (The U.S.),
- F. Hoffmann-La Roche AG (Switzerland),
- GlaxoSmithKline PLC (UK),
- Lupin Pharmaceuticals Inc. (India),
- Macleods Pharmaceuticals Ltd (India),
- Mankind Pharma (India),
- Merck & Co. Inc. (The U.S.),
- Pfizer Inc. (The U.S.), and
- Teva Pharmaceutical Industries Ltd. (Israel).
Features of the Report
This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools.
The Cephalosporin analysis report discusses the following heads in great detail:
- Market structure: Overview, industry life cycle analysis, supply chain analysis
- COVID-19 Impact Assessment
- Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
- Market trend and forecast analysis
- Market segment trend and forecast
- Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
- Attractive market segments and associated growth opportunities
- Emerging trends
- Strategic growth opportunities for the existing and new players
- Key success factors
Know more about Stratview Research:
Stratview Research is a global market research company and is known to offer custom research reports in varied fields such as aerospace & Defense, Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas. Our team makes sure to have deep research about the topics so that the most useful insights can be delivered to the professionals.
Need a detailed report? Get in touch with us:
E-mail: [email protected]arch.com